Navigation Links
New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/16/2008

BRIDGEWATER, N.J., May 16 /PRNewswire/ -- Data from three studies evaluating associations between lower mean baseline hemoglobin (Hb) levels and the rate of blood transfusions, as well as the possible effect of restrictions on reimbursement for erythropoiesis-stimulating agents (ESAs) in Medicare patients on the nation's blood supply, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting later this month. The meeting will take place in Chicago from May 30 to June 3, 2008.

Data from the following studies will be presented:

Transfusion Outcomes in Erythropoiesis-Stimulating Agent (ESA)-Treated Cancer Chemotherapy Patients Based on Achieved Hemoglobin (Hb) Levels

Kay Larholt, Sc.D., Abt Associates, Lexington, MA

Presentation: Health Svcs Research, Sunday, June 1, 2008; 8:00am - 12:00pm CST, S Hall A1

Abstract Number: 6637

Last year, the Centers for Medicare and Medicaid Services (CMS) implemented a National Coverage Determination (NCD) largely eliminating coverage for non-renal ESA administration when patients have hemoglobin concentrations above 10 grams per deciliter of blood (g/dL). This study assessed the potential clinical implications of these policy changes by evaluating data from an ongoing prospective registry of ESA-treated patients in 55 U.S. oncology clinics between December 2003 and November 2007. Data were analyzed from 330 adult chemotherapy-treated oncology patients who had hemoglobin concentrations less than 10 g/dL prior to ESA administration and received two or more ESA doses. Transfusion-related outcomes were categorized based on mean Hb values achieved during ESA treatment into three cohorts: mean achieved Hb between 9.1 g/dL and 10 g/dL, between 10.1 g/dL and 11 g/dL, or between 11.1 g/dL and 12 g/dL.

Hematologic and Transfusion Outcomes Following Implementation of the Erythropoiesis-Stimulating Agent (ESA) National Coverage Determination (NCD) in Medicare Cance
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
3. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
4. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
5. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
6. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
7. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
9. Navigenics(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments
10. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
11. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Ill. , Aug. 3, 2015 Your ... problem, and you,re looking for the best possible outcome. ... the best outcome too, and now there,s a ... Following steps recommended by the American Orthopaedic Foot ... surgery can help you avoid complications and heal as ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2
... 22 Dynavax,Technologies Corporation (Nasdaq: DVAX ) today ... ragweed allergy therapy, to subjects as,part of an environmental ... of 300 subjects. Subjects are being screened based on ... Exposure to ragweed allergen in,the chamber is being used ...
... 22 Boston,Scientific Corporation (NYSE: BSX ) ... which continue to support the proven safety and,efficacy ... and add to the growing body of strong ... Coronary,Stent System. An analysis of the data was ...
Cached Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 2Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 3Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures 4
(Date:8/3/2015)... ... 03, 2015 , ... Novatus, Inc. today launched the largest ... well as announced the date of its next major release. , Version 6.0 ... tasks as well as enhancements to the customer experience. Users now enjoy ...
(Date:8/3/2015)... ... , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative ... Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in ... presentation may be accessed via the investor relations section of the Company’s website. , ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive ... occurs naturally in the body and helps absorb and breakdown fat cells. Previously, plastic ... These are invasive procedures and very expensive for most people. Now with Kybella, there ...
(Date:8/3/2015)... ... , ... From 2006-2017 the number of dental laboratories in ... compiled for the National Association of Dental Laboratories ( NADL ) by Valmont ... Statistics. As the number of dental laboratories decreases, dentists will have fewer options ...
(Date:8/3/2015)... ... 03, 2015 , ... Hub International Insurance Services ... joined its growing California employee benefits division. Mr. Williams will be responsible ... Mr. Williams will be joining the newly integrated Northern California employee benefits team ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... new method for creating nanofibers made of proteins, developed ... (NYU-Poly), promises to greatly improve drug delivery methods for ... as well as aid in the regeneration of human ... this same development could point the way to even ...
... Center for Healthy Neighborhoods of Case Western Reserve ... groups on three of the most pressing public ... The three data briefs statistical public health ... prevalence estimates for diabetes, hypertension awareness and obesity ...
... -- Even when fast-food restaurants list calorie counts for menu ... information to make healthy meal choices, researchers report. In ... 200 food items on menu boards from 12 restaurant chains ... often, calorie counts were listed for combo meals or meals ...
... at Moffitt Cancer Center in Tampa, Fla., and colleagues ... prevent resistance to the chemotherapy drug vemurafenib, commonly used ... characterized by a diminished apoptosis (programmed cancer cell death) ... and cell survival is regulated by a family of ...
... National Jewish Health has received a grant for $950,308 ... Colorado,s San Luis Valley with educational materials for patients ... is the most common chronic illness in children and ... days. The San Luis Valley has one of the ...
... of all deaths in the United States are linked to ... inactivity. Despite these causal links, of the $2 trillion spent ... of that is devoted to addressing behavioral and social risk ... in behavioral and social sciences with a new $500,000 grant ...
Cached Medicine News:Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:First breakdown of public health data for Cleveland neighborhoods 2Health News:First breakdown of public health data for Cleveland neighborhoods 3Health News:Many Gaps in Fast-Food Nutrition Information 2Health News:Researchers find potential solution to melanoma's resistance to vemurafenib 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 3Health News:Training grant targets behavioral and social factors linked to health 2Health News:Training grant targets behavioral and social factors linked to health 3
... Gentian violet ink ... prepping, Millimeter scale ruler ... barrel for quick measuring. ... with both inch and ...
Double-ended, one end sharp, other end blunt, 7 1/2", double-ended, 5 mm wide....
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
Medicine Products: